Dennis M. Lanfear
Chairman and Founder
InteKrin Therapeutics Incorporated
Mr. Lanfear joined the board of directors of Insmed Incorporated in December 2007. He was a Strategic Consultant to Insmed from 2005 up to his appointment to the board.
In 2010 Mr. Lanfear was appointed Chairman of InteKrin, the company he founded in 2005. Prior to this, he was President and CEO of InteKrin from 2005 to 2010.
From 1986 until his founding of InteKrin Mr. Lanfear was at Amgen Inc. where he was a Corporate Officer and Vice-President with broad operational, product development and marketing responsibility. He also held senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins, directing efforts from preclinical to Phase III. He reviewed and wrote sections of more that 20 INDs and several BLAs and managed several corporate partner relationships. In 1997 he was named Vice President, Market Development, where he defined long term competitive and reimbursement strategies for Epogen™, a multibillion dollar anemia drug.
Prior to joining Amgen, Mr. Lanfear held positions of increasing responsibility at Baxter International and was also the founder and former CEO of Saronyx, Inc., a drug development software services company. He is also an active life science investor through his firm Lanfear Capital Advisers, which invests in pharmaceutical and medical device companies. He is an investor and former Director of Anthera Pharmaceuticals and an investor and Board observer at EndoVx, a medical device company focused on obesity.
Mr. Lanfear earned degrees in Biochemistry and Chemical Engineering from Michigan State University and earned his MBA from the Anderson School at UCLA.
